Advertisement

Haptoglobin elutes from human atherosclerotic coronary arteries—a potential marker of arterial pathology

      Abstract

      Background: Molecules which egress from atherosclerotic arteries may function as plasma markers of arterial pathology, but such egress has not been proven with living human coronary arteries. We hypothesised that proteins eluting from the arterial wall may discriminate between atherosclerotic and non-atherosclerotic coronary arteries. Methods and results: During cardiac bypass surgery, 155 sequential fractions of antegradely flushed coronary cardioplegia solution were collected by balloon-cuffed catheter from the coronary sinus in subjects with angiographically extensive (n=30) or minor (n=7) coronary disease. Although plasma was the major source of protein in heavily blood-contaminated samples, under conditions of low blood contamination (<0.5 mg/ml red cell Haemoglobin) coronary circulation-derived protein was detected. N-terminal sequencing of a major 40 kDa band detected by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) demonstrated 100% homology with beta chain of Haptoglobin (Hpt). Comparison of perfusates from patients with and without significant coronary disease found that the concentration of Hpt was markedly increased in perfusates from atherosclerotic coronary arteries (0.099±0.017 μg Hpt/μg Hb) relative to controls (0.016±0.008 μg Hpt/μg Hb, P=0.0027). Analysis of peripheral plasma samples of the same subjects, and of a separate cohort of patients, confirmed greater Hpt in those with angiographic coronary disease than in those without disease. Conclusions: Proteins such as Hpt elute from the human coronary vascular bed and may differentiate between arteries with minor or extensive atherosclerosis. Although the suitability of Hpt as a circulating plasma marker for atherosclerosis remains to be established, the approach used in the present study may permit identification of diverse plasma-detectable markers of atherosclerosis, and the subsequent non-invasive evaluation of in vivo arterial pathology.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridker P.M.
        Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view.
        Blood Coagul. Fibrinolysis. 1999; 10: S9-12
        • Lijana R.C.
        • Williams M.C.
        Tetramethylbenzidine—a substitute for benzidine in hemoglobin analysis.
        J. Lab. Clin. Med. 1979; 94: 266-276
        • Standefer J.C.
        • Vanderjagt D.
        Use of tetramethylbenzidine in plasma hemoglobin assay.
        Clin. Chem. 1977; 23: 749-751
        • Morrissey J.H.
        Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.
        Anal. Biochem. 1981; 117: 307-310
        • Rees D.
        • Sloane T.
        • Jessup W.
        • Dean R.T.
        • Kritharides L.
        Apolipoprotein A-I stimulates secretion of apolipoprotein E by foam cell macrophages.
        J. Biol. Chem. 1999; 274: 27925-27933
        • Langlois M.R.
        • Delanghe J.R.
        Biological and clinical significance of haptoglobin polymorphism in humans.
        Clin. Chem. 1996; 42: 1589-1600
        • Alekseeva I.N.
        Acute phase blood proteins: role in the homeostasis and their synthesis induction in the liver.
        Fiziol. Zh. 1994; 40: 106-117
        • Enger R.
        Acute-phase proteins in inflammation.
        C R Seances Soc. Biol. Fil. 1995; 189: 563-578
        • Dobryszycka W.
        Biological functions of haptoglobin—new pieces to an old puzzle.
        Eur. J. Clin. Chem. Clin. Biochem. 1997; 35: 647-654
        • Turner G.A.
        Haptoglobin. A potential reporter molecule for glycosylation changes in disease.
        Adv. Exp. Med. Biol. 1995; 376: 231-238
        • Braeckman L.
        • De Bacquer D.
        • Delanghe J.
        • Claeys L.
        • De Backer G.
        Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables.
        Atherosclerosis. 1999; 143: 383-388
        • Delanghe J.
        • Cambier B.
        • Langlois M.
        • et al.
        Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery.
        Atherosclerosis. 1997; 132: 215-219
        • Stastny J.
        • Fosslien E.
        • Robertson Jr, A.L.
        Human aortic intima protein composition during initial stages of atherogenesis.
        Atherosclerosis. 1986; 60: 131-139
        • Stastny J.J.
        • Fosslien E.
        Quantitative alteration of some aortic intima proteins in fatty streaks and fibro-fatty lesions.
        Exp. Mol. Pathol. 1992; 57: 205-214
        • Smeets M.
        • Klein D.P.V.D.
        • Poppen M.
        • Lim S.K.
        • Pasterkamp G.
        The acute phase protein haptoglobin is a matrix metalloproteinase-2 inhibitor.
        Circulation. 2000; 102: 173